Pharmaceutical giant Eli Lilly and Company is making a significant investment in US manufacturing with a $5 billion state-of-the-art facility set to rise outside Richmond, Virginia. This massive undertaking underscores the company's commitment to bolstering domestic production of crucial raw materials for its medicines. The new plant, located in Goochland County, will focus on the creation of artificial antibodies designed to enhance the immune system, alongside production for innovative cancer and autoimmune treatments currently under development.
This project represents a pivotal moment for Virginia's economy. The construction phase alone is expected to generate 1,800 jobs, followed by 650 permanent, highly skilled positions in engineering, science, and laboratory technology. While minimal relocation from existing Eli Lilly sites is anticipated, the majority of roles will be filled by new hires. Virginia Governor Glenn Youngkin has lauded the project as transformative, highlighting its contribution to economic growth, strengthening the nation's pharmaceutical supply chain, and establishing Virginia as a leader in future-focused industries.
The Virginia facility is the first of four planned manufacturing plants as part of Eli Lilly's ambitious $50 billion investment in domestic manufacturing. This strategic move aims to increase the company's control over the production of key ingredients for its flagship medications, including Mounjaro and Zepbound, used in diabetes and obesity treatments. CEO Dave Ricks emphasized the project's significance, stating that it is about creating opportunities within the US and enhancing the country's ability to produce its own medicines. Construction is set to commence swiftly, with full-time hiring unfolding over the next couple of years.
State officials project a substantial economic ripple effect, estimating that every dollar invested by Eli Lilly will generate four dollars in overall economic impact within the community. The addition of life sciences jobs is expected to spur further job creation in related sectors. Virginia's proactive development of a pharmaceutical manufacturing base, particularly in the Richmond area, has played a significant role in attracting this investment. The Goochland site's location, alongside its pre-existing infrastructure, proved a strategic advantage, facilitating expedited construction, a key factor in Eli Lilly's decision.
While various factors influenced Eli Lilly's decision, including the expansion of the biopharma ecosystem in the region and the extension of corporate tax cuts, Ricks emphasized that the company's decision to reduce reliance on foreign suppliers for raw materials was made approximately five years ago. This move reflects broader concerns about national security and the vulnerability of the US pharmaceutical industry to global disruptions.
---
Originally published at: https://www.washingtonpost.com/dc-md-va/2025/09/16/eli-lilly-rchmond-virginia-factory-youngkin/
